Anti-liver cancer therapeutic targets and safety of usenamine A in experimental liver cancer
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgae096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Xiaoqiong He und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Kunming Medical University, Kunming 650500, Yunnan Province, China. Hauptthemen laut MEDLINE: Cell Proliferation, Antineoplastic Agents, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science Achievements of Kunming Medical University.
Abstract (Originalsprache)
Background
Liver cancer is highly heterogeneous with poor drug response. Usenamine A has anticancer activity. Usnic acid has hepatocytotoxicity.
Objectives
As a derivative of usnic acid, if usenamine A can be safely used in treatment for liver cancer is unknown.
Methods
MTT and clone formation assays assessed cell viability and proliferation. Tumor growth was determined using a xenograft model. Flow cytometry was used to detect the cell cycle. mRNA transcriptome sequencing investigated differential gene expression. Safety was evaluated in mice. Key findings Usenamine A inhibited proliferation and clone formation of HepG2 cells and xenograft tumor growth through cell cycle arrest at G0/G1. Usenamine A altered gene expression in a direction supporting anticancer activity. IL24, JUN, DUSP4, and DUSP5 were upregulated while PRKACA, PRKCB, TP53, WNT6, E2F3, LGR4, GPR78, and MAPK4 were downregulated. Ten of above genes overlapped in the KEGG enriched non-small cell lung cancer/glioma/cytokine–cytokine receptor interaction/Wnt/MAPK pathway network. Usenamine A has a strong binding affinity for PRKACA and PRKCB proteins. Usenamine A showed minimal toxicity in mice.
Conclusions
Usenamine A is a safe anticancer agent against hepatocellular carcinoma. Regulation of 12 cancer-associated genes and the correlated pathway network are its therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Kunming Medical University, Kunming 650500, Yunnan Province, China.
- Department of Health Management, The Second Affiliated Hospital of Xi'an Medical University, Xi'an 710038, Shanxi Province, China.
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China.
- State Key Laboratory of Phytochemistry and Plant Resources in Western China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan Province, China.
- Institute of Yunnan Tumor, The Third Affiliated Hospital (Yunnan Tumor Hospital) of Kunming Medical University, Kunming 650118, Yunnan Province, China.
ORCID-Profile: Xiaoqiong He
Förderung
- National Natural Science Foundation of China
- Science Achievements of Kunming Medical University
Zitieren
APA
He, X., Zhou, Z., Wang, J., Zhao, Q., Fan, S., Yao, Q., Lian, W., & You, Y. (2025). Anti-liver cancer therapeutic targets and safety of usenamine A in experimental liver cancer. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae096
Vancouver
He X, Zhou Z, Wang J, Zhao Q, Fan S, Yao Q, et al. Anti-liver cancer therapeutic targets and safety of usenamine A in experimental liver cancer. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae096
BibTeX
@article{He2025,
author = {He, Xiaoqiong and Zhou, Zhangping and Wang, Jing and Zhao, Qing and Fan, Shirui and Yao, Qian and Lian, Wenjing and You, Yutong},
title = {Anti-liver cancer therapeutic targets and safety of usenamine A in experimental liver cancer},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgae096}
}
EUVIMED